# Annovis Bio, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Annovis Bio, Inc.). ## Overview Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and related neurological conditions. Its lead program, buntanetap, is being advanced for Alzheimer’s disease and Parkinson’s disease, with additional patent claims covering acute brain and nerve injuries, neuropsychiatric indications, infections of the brain, and other disease areas. The company was founded in 2008 and is headquartered in Malvern, Pennsylvania. Annovis has not commercialized any product and currently operates as a single operating segment centered on research, development, and clinical execution. ## Products & services • Buntanetap clinical development for Alzheimer’s disease • Buntanetap clinical development for Parkinson’s disease • Patent portfolio for neurodegeneration and brain injury uses • Posiphen / Posiphen Form B / ANVS402 development assets • Clinical trial and regulatory development activities - **Lead therapeutic candidate development** (70%) — Development of buntanetap as a treatment for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. - **Pipeline expansion and new indications** (15%) — Research and patenting around additional uses for buntanetap in brain injury, neuropsychiatric, infectious, and oncology-related settings. - **Preclinical and follow-on assets** (10%) — Development work on Posiphen, Posiphen Form B, and ANVS402 as related proprietary compounds. - **Intellectual property and licensing value** (5%) — Patent filings and composition-of-matter protection intended to extend exclusivity and support future partnering. - Buntanetap for Alzheimer’s disease - Buntanetap for Parkinson’s disease - Buntanetap for acute brain and nerve injuries - Posiphen, Posiphen Form B, and ANVS402 - Patent families covering neurodegeneration and related indications - Clinical development and regulatory advancement of product candidates ## Customers Annovis does not currently sell commercial products, so it has no traditional paying customer base today. Its near-term end users, if approvals are obtained, would be patients with Alzheimer’s disease, Parkinson’s disease, and potentially other neurodegenerative or neurological conditions. The company’s commercial customers would likely be healthcare providers, hospitals, specialty pharmacies, and third-party payors that determine access and reimbursement. In the current stage, the company’s key external stakeholders are clinical investigators, contract research organizations, contract manufacturers, regulators, and potential licensing or commercialization partners. - **Neurology patients** (primary) — Patients with Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders who would use buntanetap or related therapies if approved. - **Healthcare providers** (primary) — Neurologists, memory clinics, movement-disorder specialists, and hospitals that would diagnose, prescribe, and monitor treatment. - **Third-party payors** (primary) — Commercial insurers, Medicare/Medicaid, and other payors that would determine coverage, medical necessity, and reimbursement terms. - **Clinical and regulatory partners** (secondary) — CROs, CMOs, investigators, and consultants that support development, manufacturing, and regulatory submissions. - **Potential licensing partners** (secondary) — Pharmaceutical partners that could help commercialize approved products in exchange for rights or economics. - Patients with Alzheimer’s disease if buntanetap is approved - Patients with Parkinson’s disease if buntanetap is approved - Healthcare providers and specialists who prescribe neurological therapies - Third-party payors that decide coverage and reimbursement - Clinical investigators and CROs supporting trial execution - Potential licensing or commercialization partners ## Geography Annovis is headquartered in Malvern, Pennsylvania, and substantially all of its assets are located in the United States. The company’s development and financing activities are primarily U.S.-based, and it currently has no commercial revenue footprint. Its patent strategy explicitly includes protection in the United States and jurisdictions outside the United States, indicating an intent to preserve optionality for future international development or partnering. If products are approved, geography will matter materially because reimbursement, regulatory requirements, and commercialization capabilities differ by country. - Headquartered in Malvern, Pennsylvania - Substantially all assets are located in the United States - Current operations are primarily U.S.-based clinical development and financing - Patent filings extend beyond the United States to foreign jurisdictions - Future commercialization would likely require country-by-country regulatory approval - International reimbursement systems could affect adoption and pricing ## Strategy Annovis’ strategy is centered on advancing buntanetap through late-stage clinical development and regulatory review in Alzheimer’s disease and Parkinson’s disease. The company is also broadening the intellectual-property estate around additional neurological, infectious, and other potential indications to extend the commercial life of its platform. Because it has no product revenue and no internal sales infrastructure, financing remains a core strategic priority and the company relies on equity offerings, debt, and collaboration or licensing arrangements to fund operations. A successful strategy depends on completing trials, securing approvals, and then either building commercialization capabilities or partnering with larger pharmaceutical companies. - **Complete clinical development of buntanetap** (short-term) — Clinical readouts and regulatory progress are the main value drivers for a company with no commercial revenue. - **Secure additional financing** (short-term) — The company states it does not have sufficient capital to fund operations for the next 12 months and needs additional funding to continue development. - **Strengthen and extend intellectual property** (medium-term) — Patent protection is essential for future exclusivity, partnering leverage, and eventual commercial value. - **Prepare for commercialization or partnering** (medium-term) — The company has no internal sales, marketing, or distribution capabilities and will need a route to market if approval is achieved. - Advance buntanetap through clinical trials and regulatory submissions - Target Alzheimer’s disease and Parkinson’s disease as lead indications - Expand patent coverage to extend exclusivity and support partnering - Pursue additional indications to broaden the platform’s value - Raise capital through equity, debt, and collaboration structures - Potentially partner for commercialization rather than build a full sales force ## Risks Annovis faces the classic risks of a clinical-stage biotechnology company: trial failure, regulatory delay, and the possibility that approved products never achieve commercial uptake. The company has no product revenue, limited cash runway, and a stated need for additional capital, so financing risk is immediate and material. It also depends on CROs and CMOs for trial execution and manufacturing, which creates quality, compliance, and supply-chain risk outside its direct control. If buntanetap is approved, reimbursement, pricing pressure, and competition from much larger pharmaceutical companies could materially limit adoption and economics. - **Need for additional capital** [critical] — The company states it does not have sufficient capital to fund operations for the next 12 months and will need substantial additional financing. - **Clinical development failure** [critical] — Buntanetap is still in development, and negative trial results would materially impair the company’s prospects. - **Commercialization and reimbursement risk** [high] — Even if approved, third-party payors may not view the therapy as medically necessary or cost-effective. - **Manufacturing and CMO dependence** [high] — The company relies on third-party manufacturers and has limited control over cGMP compliance and supply continuity. - **Competition from larger biopharma companies** [medium] — Competitors have greater resources, broader pipelines, and more established commercialization capabilities. - Clinical trial failure or delays could eliminate or postpone the lead asset’s value - Insufficient cash and ongoing losses create near-term financing risk - Dependence on external CROs and CMOs reduces control over execution and quality - Reimbursement and payor resistance could limit access even after approval - Competition from larger pharmaceutical companies could pressure market share - Regulatory and compliance obligations could delay or block commercialization - Patent challenges or weaker-than-expected exclusivity could reduce long-term value ## Accounting The most important accounting issue for Annovis is that it has no product revenue and therefore reports results driven almost entirely by research and development, general and administrative spending, and financing-related fair value changes. Clinical-stage biotech companies often have highly judgmental estimates around stock-based compensation, accrued clinical trial costs, and vendor invoices that may arrive after period-end, which can shift quarterly expense recognition. The company also reports gains or losses from the fair value remeasurement of warrants, which can create significant non-operating volatility unrelated to core operations. Because it relies on equity financings and warrant structures, dilution, warrant valuation, and cash runway are important analytical considerations even though they are not revenue-recognition issues. - **Accrued clinical trial and development costs** — Can materially affect quarterly R&D expense and accrued liabilities - **Warrant fair value accounting** — Can distort net income/loss trends and comparability - **Stock-based compensation** — Raises G&A and R&D expenses without cash outflow - **Going concern and liquidity assessment** — Affects investor assessment of financing risk and dilution - No product revenue, so operating results are driven by R&D and G&A spending - Accrued clinical trial and CRO/CMO costs can shift between quarters - Stock-based compensation affects reported operating expenses - Warrant fair value remeasurement can create large non-cash gains or losses - Equity offerings and warrant exercises affect dilution and liquidity - Cash runway estimates are critical because the company is a going concern risk profile --- *Last updated: 2026-08-11T04:46:20.983343+00:00*